Analyst consensus rating
Benitec Biopharma Analyst Rating: Strong Buy
Direct answer
Benitec Biopharma's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $23.29.
Forecast evidence checked November 14, 2026.
Get free Benitec Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.04
- Average price target
- $23.29
- High price target
- $32.00
- Low price target
- $17.00
- Low target gap
- +88.1%
- Target upside
- +157.6%
- High target gap
- +254%
- Target range width
- 165.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Benitec Biopharma?
Benitec Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $23.29.
How far are Benitec Biopharma's low and high targets from the recorded price?
The low target implies +88.1%, while the high target implies +254%.
How many analysts are included in Benitec Biopharma's consensus?
The verified consensus includes 7 analysts.
How is Benitec Biopharma's target upside or downside calculated?
The average target of $23.29 is divided by the recorded price of $9.04, then one is subtracted to produce +157.6%. This does not guarantee a future return.
When was Benitec Biopharma's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.